Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.

Autor:	Ilie SM; Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France., Briot N; Department of Biostatistics Georges Francois Leclerc Cancer Centre, Dijon, France., Constatin G; Department of Biostatistics Georges Francois Leclerc Cancer Centre, Dijon, France., Ilie A; Cancer Biology Research Platform, Centre Georges Francois Leclerc, Dijon, France., Beltjens F; Department of Bio-pathology, Georges Francois Leclerc Cancer Centre, Dijon, France., Ladoire S; Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.; Cancer Biology Research Platform, Centre Georges Francois Leclerc, Dijon, France., Desmoulins I; Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France., Hennequin A; Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France., Bertaut A; Department of Biostatistics Georges Francois Leclerc Cancer Centre, Dijon, France., Coutant C; Surgery Department Georges Francois Leclerc Cancer Centre, Dijon, France., Causeret S; Surgery Department Georges Francois Leclerc Cancer Centre, Dijon, France., Ghozali N; Department of Medical Oncology, University Hospital Mohammed VI, Tangier, Morocco., Coudert B; Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France., Arnould L; Department of Bio-pathology, Georges Francois Leclerc Cancer Centre, Dijon, France.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Jan 10; Vol. 13, pp. 1309890. Date of Electronic Publication: 2024 Jan 10 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1309890
Abstrakt:	Background: The persistence of residual tumour after neoadjuvant chemotherapy (NAC) in localised triple-negative breast cancer (TNBC) is known to have a negative prognostic value. However, different degrees of expression of some immunohistochemical markers may correlate with different prognoses. Methods: The expression of biomarkers with a known prognostic value, i.e., cytokeratin 5/6 (CK5/6), androgen receptor (AR), epidermal growth factor receptor (EGFR) proliferation-related nuclear antigen Ki-67, human epidermal growth factor receptor 2 (HER2), protein 53 (p53), forkhead box protein 3 (FOXP3), and cluster differentiation 8 (CD8), was analysed by immunohistochemistry in 111 samples after NAC in non-metastatic TNBC patients addressed to Georges-François Leclerc Cancer Centre Dijon, France. Clinical and pathological variables were retrospectively collected. Cox regression was used to identify immunohistochemical (IHC) and clinicopathological predictors of event-free survival (EFS) (relapse or death). Results: Median age was 50.4 years (range 25.6-88.3), 55.9% (n = 62) were non-menopausal, 70 (63.1%) had stage IIA-IIB disease. NAC was mostly sequential anthracycline-taxanes (72.1%), and surgical intervention was principally conservative (51.3%). We found 65.7% ypT1, 47.2% lymph node involvement (ypN+), and 29.4% lymphovascular invasion (LVI). Most residual tumours were EGFR >110 (H-score) (60.5%, n = 66), AR ≥4% (53.2%, n = 58), p53-positive mutated (52.7%, n = 58), CD8 ≥26 (58.1%, n = 61), FOXP3 ≥7 (51.4%, n = 54), more than half in the stroma, and 52.3% (n = 58) HER2 score 0. After a median follow-up of 80.8 months, 48.6% had relapsed. Median EFS was 62.3 months (95% CI, 37.2-not reached (NR)). Factors independently associated with poor EFS were AR-low (p = 0.002), ypN+ (p < 0.001), and LVI (p = 0.001). Factors associated with lower overall survival (OS) were EGFR-low (p = 0.041), Ki-67 high (p = 0.024), and ypN+ (p < 0.001). Conclusion: Post-NAC residual disease in TNBC showed biomarkers specific to a basal-like subtype and markers of lymphocyte infiltration mostly present in the stroma. Prognostic markers for EFS were AR, LVI, and ypN and warrant further validation in a prognostic model. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Ilie, Briot, Constatin, Ilie, Beltjens, Ladoire, Desmoulins, Hennequin, Bertaut, Coutant, Causeret, Ghozali, Coudert and Arnould.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu